Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with indolent lymphomas.
Mathias Rummel, MD, PhD: Bendamustine-Rituximab “StiL” Beats R-CHOP for Indolent Lymphomas
